Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| ImageneBio | 2026 | Post-IPO Equity | Undisclosed | San Diego |
| Sionna Therapeutics | 2024 | Series C | Undisclosed | Natick |
| Apollomics | 2026 | Post-IPO Debt | Undisclosed | Foster City |
| Lomond Therapeutics | 2025 | Venture - Series Unknown | Undisclosed | San Diego |
| Pinnacle Medicines | 2026 | Series B | Undisclosed | Doylestown |
| Nkarta Therapeutics | 2024 | Post-IPO Equity | Undisclosed | South San Francisco |
| Capstan Therapeutics | 2024 | Series B | Undisclosed | San Diego |
| Harvest Integrated Research Organization | 2022 | Series A | Undisclosed | Excelsior |
| QuantX Biosciences | 2026 | Series B | Undisclosed | Princeton |
| Tyra Biosciences | 2024 | Post-IPO Equity | Undisclosed | Carlsbad |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | ImageneBio | Post-IPO Equity | Undisclosed | San Diego, United States |
| 27 | Sionna Therapeutics | Series C | Undisclosed | Natick, United States |
| 28 | Apollomics | Post-IPO Debt | Undisclosed | Foster City, United States |
| 29 | Lomond Therapeutics | Venture - Series Unknown | Undisclosed | San Diego, United States |
| 30 | Pinnacle Medicines | Series B | Undisclosed | Doylestown, United States |
| 31 | Nkarta Therapeutics | Post-IPO Equity | Undisclosed | South San Francisco, United States |
| 32 | Capstan Therapeutics | Series B | Undisclosed | San Diego, United States |
| 33 | Harvest Integrated Research Organization | Series A | Undisclosed | Excelsior, United States |
| 34 | QuantX Biosciences | Series B | Undisclosed | Princeton, United States |
| 35 | Tyra Biosciences | Post-IPO Equity | Undisclosed | Carlsbad, United States |
ImageneBio is dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases
Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
Apollomics is a biopharmaceutical company discovering and developing mono- and combination- oncology therapies to harness the immune system.
Lomond Therapeutics creates pharmacological platforms that target escape mutations.
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs.
Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies.
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO).
QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions.
Leal Therapeutics develops novel therapeutics for patients.
ProVerum Medical is a medtech company that develops novel minimally invasive devices to treat benign prostatic hyperplasia.
ENYO Pharma is a biopharmaceutical company based in Lyon, France.
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers.
RayThera is dedicated to developing small molecule therapies specifically targeting unmet needs in immunology.
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Aer Therapeutics, a clinical-stage biopharmaceutical company developing therapeutic solutions for muco-obstructive lung diseases.
Helicore Biopharma is a biopharmaceutical company that discovers and develops novel weight-loss therapeutics.
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.
OrbiMed has invested in 239 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
OrbiMed's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Biopharma. The firm invests across 13 different industry categories.
Among tracked funding rounds, Treeline Biosciences received $200.0M in a Series A round. OrbiMed's total known invested capital is $12.2B.
OrbiMed's average investment size is $87.5M across its portfolio of 239 companies.
Recent OrbiMed portfolio additions include ImageneBio, Sionna Therapeutics, Apollomics, Lomond Therapeutics, Pinnacle Medicines. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors